Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

@article{Baigent2005EfficacyAS,
  title={Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins},
  author={Colin Baigent and Anthony C. Keech and Patricia M. Kearney and Lisa Blackwell and Georgina Buck and Christine A Pollicino and Adrienne Kirby and Tatiana Sourjina and Richard Peto and Rory Collins and R John Simes},
  journal={The Lancet},
  year={2005},
  volume={366},
  pages={1267-1278}
}

Figures from this paper

The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials
TLDR
A meta-analysis of randomized controlled trials that compared different intensities of statin therapy found insufficient evidence to advocate treating to particular LDL targets, using combination lipid-lowering therapy to achieve these targets or for using more intensive regimens in patients without established coronary artery disease.
Lack of Effect of Lowering LDL Cholesterol on Cancer: Meta-Analysis of Individual Data from 175,000 People in 27 Randomised Trials of Statin Therapy
TLDR
There was no evidence of any effect of reducing LDL-C with statin therapy on cancer incidence or mortality at any of 23 individual categories of sites, with increasing years of treatment, for any individual statin, or in any given subgroup.
Evidence for more intensive cholesterol lowering
TLDR
A meta-analysis of all randomized controlled trials with CVD end-points concludes that when initial LDL cholesterol exceeds 4’mmol/l and absolute CVD risk demands it, a target value of 1.8 mmol /l should be achieved, if necessary by adding ezetimibe and/or PCSK9 inhibitors to statin treatment.
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
TLDR
In patients without established cardiovascular disease but with cardiovascular risk factors, statin use was associated with significantly improved survival and large reductions in the risk of major cardiovascular events.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials.
TLDR
The association between reduction of cholesterol concentrations and deaths not related to illness warrants further investigation and the failure of cholesterol lowering to affect overall survival justifies a more cautious appraisal of the probable benefits of reducing cholesterol concentrations in the general population.
The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.
TLDR
It is demonstrated that the benefit of cholesterol-lowering therapy extends to the majority of patients with coronary disease who have average cholesterol levels and was also greater in patients with higher pretreatment levels of LDL cholesterol.
Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.
TLDR
Pravastatin therapy reduced mortality from coronary heart disease and overall mortality, as compared with the rates in the placebo group, as well as the incidence of all prespecified cardiovascular events in patients with a history of myocardial infarction or unstable angina who had a broad range of initial cholesterol levels.
Assessing possible hazards of reducing serum cholesterol
TLDR
There is no evidence that low or reduced serum cholesterol concentration increases mortality from any cause other than haemorrhagic stroke, and this risk affects only those people with a very low concentration and even in these will be outweighed by the benefits from the low risk of ischaemic heart disease.
...
1
2
3
4
5
...